Seizure News and Research RSS Feed - Seizure News and Research

An epileptic seizure, occasionally referred to as a fit, is defined as a transient symptom of "abnormal excessive or synchronous neuronal activity in the brain".
Treatment outcomes in type 1 diabetes could be improved across all age groups

Treatment outcomes in type 1 diabetes could be improved across all age groups

In a sweeping analysis assessing the current state of diabetes treatment in the U.S., T1D Exchange researchers conclude that there remains considerable room for improving treatment outcomes in type 1 diabetes across all age groups, but especially for adolescents and young adults. [More]
Discovery has clear implications in the quest for new epilepsy treatments

Discovery has clear implications in the quest for new epilepsy treatments

The mission of neural stem cells located in the hippocampus, one of the main regions of the brain, is to generate new neurons during the adult life of mammals, including human beings, of course, and their function is to participate in certain types of learning and responses to anxiety and stress. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
DNMT1 gene essential to maintain breast and cancer stem cells

DNMT1 gene essential to maintain breast and cancer stem cells

The gene and hormone soup that enables women to breastfeed their newborns also can be a recipe for breast cancer, particularly when the first pregnancy is after age 30. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV. [More]
Electroclinical triggers for repeat MRI in intractable epilepsy identified

Electroclinical triggers for repeat MRI in intractable epilepsy identified

Researchers have outlined the electroclinical features typically associated with bottom-of-sulcus dysplasia, the surgical removal of which often cures epilepsy in affected patients. [More]
Parents share arduous, circuitous journey to get referrals for childhood epilepsy surgery

Parents share arduous, circuitous journey to get referrals for childhood epilepsy surgery

Having a child diagnosed with epilepsy can be a frightening and confusing time. Now, parents share their arduous and "circuitous" journey to get referrals for pediatric epilepsy surgery once their child's disease stops responding to anti-seizure medications. The UCLA study sheds light on the difficulties parents face obtaining specialty and sub-specialty care for their children during an already stressful time. [More]
Understanding how nerve cells in the brain produce energy required to function

Understanding how nerve cells in the brain produce energy required to function

New research published today in the journal Nature Communications represents a potentially fundamental shift in our understanding of how nerve cells in the brain generate the energy needed to function. The study shows neurons are more independent than previously believed and this research has implications for a range of neurological disorders. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
New CUMC study finds DNA anomalies in kids with chronic kidney disease

New CUMC study finds DNA anomalies in kids with chronic kidney disease

A significant proportion of children with chronic kidney disease (CKD) have unsuspected chromosomal imbalances, including DNA anomalies that have been linked to neurocognitive disorders, according to a new Columbia University Medical Center study. [More]
Electronic micropump combined with anticonvulsant drug may treat brain diseases

Electronic micropump combined with anticonvulsant drug may treat brain diseases

Many potentially efficient drugs have been created to treat neurological disorders, but they cannot be used in practice. Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain. [More]
New priority program set to develop next generation of optogenetic tools

New priority program set to develop next generation of optogenetic tools

Optogenetics is a new field of research that introduces light-sensitive proteins into cells in a genetically targeted manner, for example, to obtain information on signalling pathways and the function of neurons in a living organism. [More]
Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. [More]
One in five college students experiences exploding head syndrome

One in five college students experiences exploding head syndrome

Washington State University researchers have found that an unexpectedly high percentage of young people experience "exploding head syndrome," a psychological phenomenon in which they are awakened by abrupt loud noises, even the sensation of an explosion in their head. [More]
Only few studies demonstrate the effectiveness of marijuana

Only few studies demonstrate the effectiveness of marijuana

While many states have pushed for new laws to legalize the use of marijuana for medical reasons, there are few well-controlled studies that demonstrate its effectiveness. [More]
Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI). [More]
Anxiety and déjà vu: an interview with Dr Christine Wells, Sheffield Hallam University

Anxiety and déjà vu: an interview with Dr Christine Wells, Sheffield Hallam University

It’s thought that the neural basis of déjà vu is located in the temporal lobes, a region of the brain strongly associated with the storage and retrieval of memories. One source of support for this is evidence from individuals with temporal lobe epilepsy, some of whom experience déjà vu episodes as part of seizure-related auras... [More]
Direct brain responsive neurostimulator reduces seizures, improves quality of life

Direct brain responsive neurostimulator reduces seizures, improves quality of life

Piotr Olejniczak, MD, PhD, LSU Health New Orleans Professor of Neurology and Director of the Epilepsy Center, contributed to a study of the long-term effectiveness of the first direct brain responsive neurostimulator for partial onset, or focal, seizures that cannot be controlled with medication. [More]
LSU Health New Orleans finalizes deal with CB BioSciences

LSU Health New Orleans finalizes deal with CB BioSciences

The Office of Technology Management at LSU Health New Orleans has finalized a deal with CB BioSciences, Inc., a startup drug development company to build a platform around the intellectual property portfolio of Chu Chen, PhD, LSU Health New Orleans Professor of Neuroscience. [More]
Advertisement